Getinge (SE:GETI.B)
:GETI.B
Want to see SE:GETI.B full AI Analyst Report?
Top Page
Getinge
(GETI.B)
Select Model
Select Model
Rating:69Neutral
Price Target:
kr217.00
▲(0.05% Upside)
Action:Reiterated
Date:04/22/26
The score is primarily supported by resilient fundamentals and strong, improving free cash flow generation, which outweigh the recent revenue softness and gradually higher leverage. Technicals are moderately constructive in the short term but weaker on longer-term trend signals, while valuation is fair with no dividend support.
Positive Factors
Strong free cash flow generation
Sustained, high-quality free cash flow (3.3B, +25.9% TTM and ~72% conversion) provides durable internal funding for R&D, service expansion, capex and debt reduction. This strengthens financial flexibility and supports long‑term reinvestment independent of short-term revenue swings.
Negative Factors
Near-term revenue weakness
A TTM revenue decline (-2.5%) signals a pause in top-line momentum that can constrain scale benefits and capex returns. If persistent, weaker organic growth limits service attach expansion and reduces the pace at which improved cash flow can translate into higher long‑term profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong free cash flow generation
Sustained, high-quality free cash flow (3.3B, +25.9% TTM and ~72% conversion) provides durable internal funding for R&D, service expansion, capex and debt reduction. This strengthens financial flexibility and supports long‑term reinvestment independent of short-term revenue swings.
Read all positive factors
Getinge (GETI.B) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr52.81B
Dividend Yield2.16%
Average Volume (3M)472.77K
Price to Earnings (P/E)22.4
Beta (1Y)0.81
Revenue Growth-4.14%
EPS Growth59.50%
CountrySE
Employees11,827
SectorGeneral
Sector StrengthN/A
IndustryMedical - Devices
Share Statistics
EPS (TTM)8.66
Shares Outstanding254,152,370
10 Day Avg. Volume671,507
30 Day Avg. Volume472,771
Financial Highlights & Ratios
PEG Ratio0.70
Price to Book (P/B)2.03
Price to Sales (P/S)1.70
P/FCF Ratio22.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr260.00Price Target Upside19.87% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)11.42
Revenue Forecast (FY)kr34.88B
Getinge Business Overview & Revenue Model
Company Description
Getinge AB, founded in 1904 and headquartered in Gothenburg, Sweden, is a prominent global supplier of medical technology solutions. The company's extensive portfolio is designed for critical healthcare environments, including operating rooms, int...
How the Company Makes Money
Getinge makes money primarily by selling medical technology products and integrated solutions to hospitals, healthcare providers, and life science/pharmaceutical customers, complemented by recurring revenue from services. Key revenue streams inclu...
Getinge Financial Statement Overview
Summary
Income Statement
67
Positive
Balance Sheet
74
Positive
Cash Flow
79
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 34.09B | 34.97B | 34.76B | 31.83B | 28.29B | 27.05B |
| Gross Profit | 15.58B | 15.54B | 16.15B | 14.49B | 13.41B | 13.58B |
| EBITDA | 6.01B | 5.85B | 5.31B | 5.93B | 5.73B | 6.15B |
| Net Income | 2.36B | 2.26B | 1.64B | 2.41B | 2.49B | 2.97B |
Balance Sheet | ||||||
| Total Assets | 58.02B | 56.51B | 63.92B | 53.59B | 52.03B | 44.55B |
| Cash, Cash Equivalents and Short-Term Investments | 4.02B | 3.40B | 2.96B | 2.73B | 5.68B | 4.08B |
| Total Debt | 10.99B | 10.88B | 10.73B | 8.08B | 5.82B | 4.31B |
| Total Liabilities | 26.98B | 27.01B | 30.71B | 23.18B | 21.58B | 19.38B |
| Stockholders Equity | 30.98B | 29.43B | 33.01B | 30.17B | 30.04B | 24.75B |
Cash Flow | ||||||
| Free Cash Flow | 3.31B | 2.63B | 3.27B | 1.60B | 2.23B | 5.63B |
| Operating Cash Flow | 4.58B | 3.95B | 4.58B | 2.96B | 3.37B | 6.56B |
| Investing Cash Flow | -2.82B | -2.96B | -4.55B | -6.54B | -1.47B | -1.33B |
| Financing Cash Flow | -2.09B | -765.00M | 504.00M | 511.00M | -500.00M | -7.24B |
Getinge Technical Analysis
Positive
216.90
Price Trends
191.49
Positive
191.11
Positive
199.81
Negative
Market Momentum
0.90
Negative
53.19
Neutral
59.31
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:GETI.B, the sentiment is Positive. The current price of 216.9 is above the 20-day moving average (MA) of 192.22, above the 50-day MA of 191.49, and above the 200-day MA of 199.81, indicating a neutral trend. The MACD of 0.90 indicates Negative momentum. The RSI at 53.19 is Neutral, neither overbought nor oversold. The STOCH value of 59.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:GETI.B.
Getinge Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | kr54.01B | 94.59 | 27.98% | 0.43% | 9.32% | 0.07% | |
73 Outperform | kr7.96B | 107.81 | 1.20% | ― | -2.39% | -46.09% | |
69 Neutral | kr52.81B | 22.39 | 6.91% | 2.16% | -4.14% | 59.50% | |
67 Neutral | kr3.26B | 24.34 | 17.89% | 1.61% | -2.32% | -11.87% | |
58 Neutral | kr12.33B | -2.46 | 3.34% | 0.80% | -5.68% | -1106.19% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
49 Neutral | kr806.62M | -20.41 | -4.42% | ― | 4.66% | 27.83% |
* General Sector Average
SE:GETI.B
Getinge
193.90
15.53
8.71%
SE:VITR
Vitrolife AB
91.05
-44.55
-32.86%
SE:CEVI
CellaVision AB
136.80
-41.24
-23.16%
SE:XVIVO
Xvivo Perfusion AB
252.80
-26.60
-9.52%
SE:SECT.B
Sectra AB Class B
276.80
-34.98
-11.22%
SE:SEDANA
Sedana Medical AB
8.12
-2.06
-20.24%
Getinge Corporate Events
Getinge AGM Backs Dividend, Board Lineup and Share Buyback Mandate
Apr 21, 2026
Getinge’s annual general meeting approved the 2025 financial statements, re-elected most of the board and its chairman, and added Camilla Sylvest as a new director, while also confirming employee-appointed board representatives. Shareholders...
Getinge Delivers Q1 Organic Growth, Strong Cash Flow and New Regulatory Wins
Apr 21, 2026
Getinge reported modest organic growth in the first quarter of 2026, with order intake up 3.9% and net sales edging 0.8% higher despite a sharp negative currency effect that drove a 10.5% reported sales decline. Performance was mixed across busine...
Getinge Sets April 21 Date for Q1 2026 Results and Investor Call
Apr 7, 2026
Getinge will publish its first‑quarter 2026 results on April 21 and will host a same‑day conference call led by President and CEO Mattias Perjos and CFO Agneta Palmér. Fund managers, analysts and media can join via teleconference ...
Getinge Showcases Global Scale and Life-Saving Focus in 2025 Annual Report
Mar 26, 2026
Getinge’s 2025 annual report highlights a business generating SEK 35 billion in net sales, supported by a workforce of roughly 12,000 employees and a customer base of about 30,000 across more than 135 countries. The release underscores the c...
Getinge Sets April 21 Date and Voting Rules for 2026 AGM
Mar 12, 2026
Getinge AB has called its 2026 Annual General Meeting for April 21 in Halmstad, Sweden, inviting shareholders to participate either in person or via postal voting in line with its Articles of Association. Shareholders must be recorded in Euroclear...
Getinge Ends 2025 With Record Q4, Strong Organic Growth and Higher Underlying Profitability
Jan 27, 2026
Getinge reported a record fourth quarter and full-year 2025 organic sales growth of 4.9%, at the upper end of its guidance, driven by higher demand for ECLS consumables, acute care therapies, transplant care and ventilators, while Surgical Workflo...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.